) F) |. ]4 E4 j2 Y# o) i
临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:0 G( \& n- J' \
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.( @# c5 l' z+ Z) o- W http://www.ncbi.nlm.nih.gov/pubmed/229681841 N. I: y. S7 l0 p* v0 e- N